AIM ImmunoTech Inc. (AIM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Ind ...

– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces – Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by the National Cancer Institute, AstraZeneca and Merck OCALA, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) ...

Company Overview - Plantible, founded in 2018, has developed a vertically integrated manufacturing platform to produce Rubi Protein™ from Lemna (duckweed), a plant-based protein that mimics the quality, taste, and texture of animal-based proteins and replaces synthetic emulsifiers and binders [1][5][6] - CH4 Global aims to reduce methane emissions in cattle by up to 90% using its flagship product, Methane Tamer™, a feed additive leveraging Asparagopsis seaweed [6][10][12] Industry Impact - Plantible's Rubi Protein™ addresses the food industry's need for cleaner, healthier, and allergen-friendly alternatives to unsustainable ingredients [1] - CH4 Global's Methane Tamer™ reduces methane emissions from cattle, a significant contributor to climate change, while improving feed efficiency and cattle growth or milk production [2][10][12] Strategic Investments - Chipotle's Cultivate Next venture fund has made minority investments in Plantible and CH4 Global to support their missions and align with Chipotle's goal of cultivating a better world [4][7][8] - The investment in CH4 Global will help scale production of Methane Tamer™ to meet global demand, targeting the world's 1.5 billion cattle [11][12] Technological Advancements - Plantible's manufacturing technology leverages the aquatic growth of Lemna, minimizes fresh water usage through recirculation, and reduces carbon emissions due to its efficient growing process [1] - CH4 Global's Asparagopsis-based solution not only reduces methane emissions but also improves energy and nutrition absorption in cattle, enhancing growth and milk production efficiency [2][10] Market Expansion - Chipotle plans to operate 7,000 restaurants in North America, supported by investments in innovative companies like Plantible and CH4 Global through its Cultivate Next fund [4][8] - Plantible and CH4 Global are part of Chipotle's broader portfolio, which includes companies focused on sustainable and innovative food solutions [8][9]

A Plan for Compliance has been UndertakenOCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated December 11, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. This is an issue previously disclosed in our most recent Report on Form 10-Q. Specifically, the letter states that the Co ...

OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 — a compositions and methods patent — covering Ampligen® (rintatolimod) for use in the treatment of the post-COVID condition of fatigue. The patent inventors, AIM CEO Thomas K. Equels and AIM Medical Officer David R. Strayer, M.D., have assigned the granted patent to the Company. AIM CEO ...

Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating s ...

Incumbent Board’s Claims of Progress Are Not Credible or Supported by DataAIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Investors about the Timeline and Status of Regulatory Submissions to the U.S. FDAAccording to ISS – “The lack of transparency gives the impression that the company’s pipeline is more advanced and that the company is more involved than it actually is”1 Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with StockholdersKellner Group Urges ...

Kellner Group Has Financial Resources AIM Needs Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders AIM Cash Conservation Plan is Too Little Too Late, Exposes Desperate Financial Condition AIM Stock Price has Declined 99+% Frantic AIM Board Doubles Down on Attempts to Deceive Stockholders NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweene ...

OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study evaluating AIM ImmunoTech’s drug Ampligen® (also known as rintatolimod) as a component of a chemokine-modulating (CKM) regimen in early-stage triple-negative breast cancer (TNBC). Results of the study were reported in The Journal for ImmunoTherapy of Cancer. “We are very excited with these promisi ...

AIM ImmunoTech Inc. (NYSE:AIM) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Third Quarter 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. [Operator Instructions] Following the presentation, there will be a question-and-answer sess ...